MX2010008638A - Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas. - Google Patents

Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas.

Info

Publication number
MX2010008638A
MX2010008638A MX2010008638A MX2010008638A MX2010008638A MX 2010008638 A MX2010008638 A MX 2010008638A MX 2010008638 A MX2010008638 A MX 2010008638A MX 2010008638 A MX2010008638 A MX 2010008638A MX 2010008638 A MX2010008638 A MX 2010008638A
Authority
MX
Mexico
Prior art keywords
furo
thieno
pyridines
pyridine
including conditions
Prior art date
Application number
MX2010008638A
Other languages
English (en)
Inventor
Xin Chen
Arno G Steinig
Qinghua Weng
Hanqing Dong
Meizhong Jin
Mark J Mulvihill
Jing Wang
Ti Wang
An-Hu Li
Andrew Kleinberg
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of MX2010008638A publication Critical patent/MX2010008638A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de furo[3,2-c]piridina y tieno[3,2-c]piridina de la fórmula (I), y sales farmacéuticamente aceptables de los mismos, preparación, intermediarios, composiciones farmacéuticas y uso, tal como en tratamiento de enfermedad, incluyendo cánceres, incluyendo condiciones en las cuales EMT está implicado, incluyendo condiciones mediadas por actividad de proteína cinasa tal como RON y/o MET.
MX2010008638A 2008-02-06 2009-02-06 Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas. MX2010008638A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6380008P 2008-02-06 2008-02-06
US11955308P 2008-12-03 2008-12-03
PCT/US2009/033311 WO2009100282A1 (en) 2008-02-06 2009-02-06 Furo-and thieno[3,2-c] pyridines

Publications (1)

Publication Number Publication Date
MX2010008638A true MX2010008638A (es) 2010-08-30

Family

ID=40524808

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008638A MX2010008638A (es) 2008-02-06 2009-02-06 Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas.

Country Status (19)

Country Link
US (1) US8022206B2 (es)
EP (1) EP2265616B8 (es)
JP (1) JP2011511094A (es)
KR (1) KR20110014971A (es)
CN (1) CN102007127A (es)
AR (1) AR070317A1 (es)
AU (1) AU2009212338A1 (es)
BR (1) BRPI0908050A2 (es)
CA (1) CA2711078A1 (es)
CL (1) CL2009000275A1 (es)
EA (1) EA201070929A1 (es)
ES (1) ES2451024T3 (es)
IL (1) IL206758A0 (es)
MX (1) MX2010008638A (es)
PE (1) PE20091414A1 (es)
TW (1) TW200944201A (es)
UY (1) UY31638A1 (es)
WO (1) WO2009100282A1 (es)
ZA (1) ZA201005554B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780922A1 (en) * 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
WO2011109593A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Substituted-5-aminopyrrolo/pyrazolopyridines
EP2566858A2 (en) * 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
US10614666B2 (en) 2011-04-20 2020-04-07 Video Gaming Technologies, Inc. Gaming machines with free play bonus mode presenting only winning outcomes
AU2012376221A1 (en) 2011-10-31 2014-06-19 David S. Baskin Compound comprising a MAO targeting/ seeker moiety for treating human gliomas
CN104364257B (zh) * 2012-03-23 2017-03-01 纪念斯隆-凯特琳癌症中心 5‑酰基‑6,7‑二氢噻吩并[3,2‑c]吡啶类化合物对胰腺及相关癌症的治疗作用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
NZ754039A (en) 2013-06-26 2021-06-25 Abbvie Inc Primary carboxamides as btk inhibitors
US9907791B2 (en) * 2014-03-14 2018-03-06 University Of Utah Research Foundation Ron inhibitors for use in preventing and treating bone loss
CN103923081B (zh) * 2014-04-14 2017-06-27 武汉光谷人福生物医药有限公司 化合物及其制备方法和应用
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN106866447A (zh) * 2017-03-30 2017-06-20 成都绿林科技有限公司 一种合成对乙酰基苯甲酰胺的方法
US10957159B2 (en) 2018-04-12 2021-03-23 Aristocrat Technologies Australia Pty Limited Gaming machine and method for displaying a free spin count-up
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
WO2024124464A1 (zh) * 2022-12-15 2024-06-20 武汉睿健医药科技有限公司 一种诱导间质细胞向上皮细胞转化及重编程的诱导剂

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159506A0 (en) * 2001-06-23 2004-06-01 Aventis Pharma Inc Pyrrolopyrimidines as protein kinase inhibitors
WO2003009852A1 (en) * 2001-07-24 2003-02-06 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003202263A1 (en) * 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
EP1590339A4 (en) 2003-01-28 2007-07-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
MXPA05009063A (es) * 2003-02-26 2005-12-12 Sugen Inc Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
WO2004100947A2 (en) * 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
PT1784396E (pt) 2004-08-26 2011-01-27 Pfizer Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
CA2578075A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
CA2601983A1 (en) * 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
JP2009504692A (ja) * 2005-08-16 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 新規４−アミノ−チエノ［３，２−ｃ］ピリジン−７−カルボン酸アミド
WO2007027855A2 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2007056625A2 (en) * 2005-11-04 2007-05-18 Smithkline Beecham Corporation Thienopyridine b-raf kinase inhibitors
RU2387650C2 (ru) * 2005-12-05 2010-04-27 Пфайзер Продактс Инк. Полиморфы с-met/hgfr ингибитора
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
WO2007111904A2 (en) 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2007124181A2 (en) 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
US7872018B2 (en) * 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
CL2008001540A1 (es) * 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
CL2008003449A1 (es) 2007-11-21 2010-02-19 Imclone Llc Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
CA2723617A1 (en) 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
KR101034351B1 (ko) 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물

Also Published As

Publication number Publication date
CN102007127A (zh) 2011-04-06
EP2265616B8 (en) 2014-01-08
EP2265616B1 (en) 2013-11-20
BRPI0908050A2 (pt) 2015-08-11
AU2009212338A1 (en) 2009-08-13
EA201070929A1 (ru) 2011-04-29
UY31638A1 (es) 2009-09-30
ZA201005554B (en) 2011-04-28
KR20110014971A (ko) 2011-02-14
AR070317A1 (es) 2010-03-31
JP2011511094A (ja) 2011-04-07
CA2711078A1 (en) 2009-08-13
EP2265616A1 (en) 2010-12-29
ES2451024T3 (es) 2014-03-26
PE20091414A1 (es) 2009-09-23
WO2009100282A1 (en) 2009-08-13
CL2009000275A1 (es) 2009-06-12
TW200944201A (en) 2009-11-01
US20090197864A1 (en) 2009-08-06
IL206758A0 (en) 2010-12-30
US8022206B2 (en) 2011-09-20

Similar Documents

Publication Publication Date Title
MX2010008638A (es) Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas.
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
JO2787B1 (en) Alternative amide derivatives and methods of use
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
TN2018000078A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
WO2008079291A3 (en) Substituted heterocycles and methods of use
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
UA92637C2 (en) Pyridine[3,4-b]pyrazinones
AU2009253235A8 (en) Polysubstituted derivatives of 2-heteroaryl-6-phenyl-imidazo[1,2- a] pyridines, and preparation and therapeutic use thereof
MX2009008486A (es) Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor.
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
MX2011012264A (es) Derivados spiro[2.4]heptano puenteados como agonistas del receptor de lipoxina a(alx) y/o de formil peptido tipo 2 (fprl2).
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX350418B (es) Inhibidores de bifluorodioxalano-amino-bencimidazol quinasa para el tratamiento de cáncer, inflamación autoinmune y trastornos del sistema nervioso central.
EP1973407A4 (en) SPIRO COMPOUNDS AND METHODS OF USE
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
WO2011042860A3 (en) New derivatives of thieno[2,3-b]pyridine and 5,6,7,8-tetrahydrothieno[2,3-b]quinoline in particular useful in the treatment of malaria

Legal Events

Date Code Title Description
FG Grant or registration